Pediatric Cancer

PEDIATRIC CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Does Larotrectinib Offer New Hope to Children With TRK Fusion-Positive Solid Tumors?

Because of the drug’s promising safety and efficacy, the first child was treated on trial only 9 months after the first adult with a TRK fusion was treated.
Recent Conference Highlights New Potential Targets for Pediatric Cancer Treatments

Advances in targeted therapy for pediatric patients were presented at the AACR Special Conference on Pediatric Cancer.

PEDIATRIC CANCER NEWS

A young patient with cancer.

COVID-19 Morbidity in Pediatric Cancer Patients Found to Be Low

May 22, 2020

Breast cancer–specific distress, though offset by psychosocial adjustment, is higher among adolescen

Fewer Children Enrolling in Pediatric Cancer Trials

May 6, 2020

Prevalence, Risks, Outcomes Associated With Pediatric Hematology/Oncology Fellow Burnout

April 30, 2020

Pedmark Receives Priority Review for Prevention of Cisplatin-Induced Ototoxicity

April 15, 2020

While survival rates of pediatric patients with cancer are greatly improved, researchers and clinici

RACE for Children Act Could Substantially Increase Studies of Pediatric Cancer Drugs

March 25, 2020

Next post in Pediatric Cancer

Childhood cancer survivors exposed to therapies that cause pulmonary dysfunction are associated with

Phase 1/2 Study of Durvalumab and Tremelimumab in Pediatric Cancer